---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-000168"
form_type: "8-K"
ticker: "CBDW"
cik: "0001877461"
company_name: "1606 CORP."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:55:13.368124+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "medium"
source: SEC EDGAR
---

# 1606 Corp. applauds Adnexus Biotechnologies' AI-developed malaria drug Trapicolast; LOI terminated but deal progressing

## Summary
- 1606 Corp. expresses strong support for strategic investment target Adnexus Biotechnologies after Trapicolast announcement.
- Trapicolast targets apicoplast and vesicular trafficking in Plasmodium; developed via Sutra™ AI platform analyzing 8M+ compounds.
- Adnexus and 1606 Corp. previously signed a LOI that terminated Nov 28, 2024; parties still moving forward to close transaction.
- CEO Austen Lambrecht highlights AI-driven innovation for global health challenges.

## SEC filing metadata
- accession: 0001477932-25-000168
- form_type: 8-K
- ticker: CBDW
- cik: 0001877461
- company_name: 1606 CORP.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1877461/000147793225000168/0001477932-25-000168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1877461/000147793225000168/onesix_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-000168
- JSON: https://secwatch.observer/filing/0001477932-25-000168.json
- Plain text: https://secwatch.observer/filing/0001477932-25-000168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.